Evidence map›Paper›PMID 40343719›Full record

Trial reportFuture oncology (London, England)2025

Reduced dose fludarabine and cyclophosphamide lymphodepletion before tumor-infiltrating lymphocyte therapy in melanoma.

Muhammad Umair Mushtaq, Haitham Abdelhakim, Luke Selby, Moazzam Shahzad, Sunil H Abhyankar, Joseph P McGuirk, Gary C Doolittle

Registry-linked trialAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06151847 (Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion Before Tumor-Infiltrating Lymphocyte Therapy With Lifileucel in Metastatic Melanoma), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06151847 phase2completednot on this map

Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion Before Tumor-Infiltrating Lymphocyte Therapy With Lifileucel in Metastatic Melanoma

TypeinterventionalSponsorUniversity of Kansas Medical CenterRan2023 to 2025Enrolled11ConditionsClinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Unresectable MelanomaArmsBiospecimen Collection, Cyclophosphamide, Echocardiography, Fludarabine, Interleukin-2
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFNα.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Muhammad Umair MushtaqDivision of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.ORCID 0000-0001-8122-0563
Haitham AbdelhakimDivision of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
Luke SelbyDivision of Colorectal and Oncologic Surgery, University of Kansas Medical Center, Kansas City, KS, USA.
Moazzam ShahzadDivision of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
Sunil H AbhyankarDivision of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
Joseph P McGuirkDivision of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
Gary C DoolittleDivision of Medical Oncology, University of Kansas Medical Center, Kansas City, KS, USA.

Funding

University of Kansas Cancer Center Paul Calabresi K12 Career Development Award for Clinical OncologyK12CA279868 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Ronald Chen · 2023 to 2026
$1.7M
NCI NIH HHS K12 CA279868
6 · The paper itself

Abstract

CLINICAL

trial registrationNCT06151847.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCyclophosphamideImmunotherapy, AdoptiveLymphocyte DepletionLymphocytes, Tumor-InfiltratingMelanomaVidarabineFemaleHumansMaleMiddle AgedTreatment OutcomeCyclophosphamidefludarabineVidarabineclinical trial protocolimmunotherapylymphodepletion chemotherapymetastatic melanomaTumor-infiltrating lymphocytes

Identifiers

PMID40343719
PMCPMC12140488

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.